These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31448711)

  • 1. Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure.
    Fu S; Chang Z; Luo L; Deng J
    Curr Top Med Chem; 2019; 19(20):1850-1866. PubMed ID: 31448711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.
    Volpe M; Carnovali M; Mastromarino V
    Clin Sci (Lond); 2016 Jan; 130(2):57-77. PubMed ID: 26637405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
    Volterrani M; Iellamo F; Senni M; Piepoli MF
    Int J Cardiol; 2017 Jan; 226():132-135. PubMed ID: 27184730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
    D'Elia E; Iacovoni A; Vaduganathan M; Lorini FL; Perlini S; Senni M
    Eur J Heart Fail; 2017 Jun; 19(6):710-717. PubMed ID: 28326642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease.
    Chen Y; Burnett JC
    Clin Chem; 2017 Jan; 63(1):108-115. PubMed ID: 28062615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
    Sutanto H; Dobrev D; Heijman J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.
    Volpe M; Santolamazza C; Tocci G
    Curr Cardiol Rep; 2016 Dec; 18(12):127. PubMed ID: 27796865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.
    Fu S; Ping P; Wang F; Luo L
    J Biol Eng; 2018; 12():2. PubMed ID: 29344085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of RAAS-natriuretic peptides in the treatment of HF: Old guys and newcomers.
    Mollace V; Gliozzi M; Capuano A; Rossi F
    Int J Cardiol; 2017 Jan; 226():126-131. PubMed ID: 27075034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neprilysin and Natriuretic Peptide Regulation in Heart Failure.
    Bayes-Genis A; Morant-Talamante N; Lupón J
    Curr Heart Fail Rep; 2016 Aug; 13(4):151-7. PubMed ID: 27260315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction.
    Quaschning T; Galle J; Wanner C
    Kidney Int Suppl; 2003 May; (84):S54-7. PubMed ID: 12694309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
    Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
    Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure.
    Chee KH; Amudha K; Hussain NA; Haizal HK; Choy AM; Lang CC
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):140-8. PubMed ID: 14608517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF.
    Rubattu S; Triposkiadis F
    Heart Fail Rev; 2017 May; 22(3):279-288. PubMed ID: 28378286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neprilysin, the kidney brush border neutral proteinase: a possible potential target for ischemic renal injury.
    Sankhe R; Kinra M; Mudgal J; Arora D; Nampoothiri M
    Toxicol Mech Methods; 2020 Feb; 30(2):88-99. PubMed ID: 31532266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A Single or Double-Edged Effect?
    Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Batiha GE
    Curr Protein Pept Sci; 2022; 23(5):321-334. PubMed ID: 35762551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.